ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

February 2, 2018: By Joan McKenna

ReVision Optics, the maker of the Raindrop Near Vision Inlay, has closed its doors, the company announced on its website.

The announcement said the inlay would no longer be sold as of Jan. 30, 2018.

The move leaves the AcuFocus KAMRA as the only US FDA-approved corneal inlay available for the treatment of presbyopia.

The Raindrop gained US approval in June 2016 for correction of presbyopia in patients who have not had cataract surgery. It also achieved marketing authorization in the European Union, South Korea, Australia, and New Zealand.

The company announced in April 2017 that surgeons had implanted a thousand Raindrops since the product’s launch in late August 2016.

Privately held ReVision was headquartered in Lake Forest, California.

It set up a hotline that would be staffed through April 30, 2018, at 1-866-934-6592.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023